financetom
Business
financetom
/
Business
/
Peloton raises 2025 revenue forecast, counts on video subscriber growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Peloton raises 2025 revenue forecast, counts on video subscriber growth
May 26, 2025 4:00 AM

(Reuters) -Fitness company Peloton Interactive ( PTON ) raised its 2025 revenue forecast on Thursday, banking on an increase in subscriptions for its instructional videos to offset slowing demand for its exercise equipment.

Peloton, which makes equipment such as spin bikes and treadmills, has been pivoting away from hardware to transition into a software-first company.

Its turnaround strategy involves pushing subscriber growth for live and on-demand workout content to accompany its products. It has also focused on boosting its B2B portfolio by attracting more corporate wellness clients to offer the fitness company's products and services at workplaces.

This quarter marks the first earnings result with new CEO Peter Stern at the helm. Stern, who was previously responsible for Ford's subscription-led digital services business as well as Apple's ( AAPL ) Sports and Fitness+ segments, has been tasked with making the shift at Peloton.

The company now expects 2025 revenue to be between $2.46 billion and $2.47 billion, reflecting an increase of $7.5 million at the midpoint of its previous forecast range.

It also increased the lower end of its full-year forecast for connected fitness subscriptions to 2.77 to 2.79 million, from 2.75 million previously. However, this still reflects a year-over-year fall of 7%.

It expects 2025 adjusted core profit in a $330 million to $350 million range, compared to an earlier forecast of $300 million to $350 million.

For the third quarter ended March 31, the company reported a loss per share of 12 cents, smaller than a loss of 45 cents last year.

It reported revenue of $624 million, down 13% but higher than Street estimates of $621.3 million, according to data compiled by LSEG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved